Sort   by:  
 Page size 
TranscriptomicsThe retinoblastoma gene is targeted for rearrangements in BRCA1-deficient basal-like breast cancer.
Breast tumors from BRCA1 germ line mutation carriers typically exhibit features of the basal-like molecular subtype. However, the specific genes recurrently mutated as a consequence of BRCA1 dysfunction have not been fully elucidated. In this study, we utilized gene expression profiling to molecular...
ORGANISM(S): Homo sapiens 
2012-06-26 | E-GEOD-25307 | biostudies-arrayexpress
TranscriptomicsCharacterization of amplification patterns and target genes at chromosome 11q13 in CCND1-amplified sporadic and familial breast tumors
Amplification of chromosomal region 11q13, containing the cell cycle regulatory gene CCND1, is frequently found in breast cancer and other malignancies. It is associated with the favourable oestrogen receptor (ER) positive breast tumour phenotype, but also with poor prognosis and treatment failure. ...
ORGANISM(S): Homo sapiens 
2011-11-23 | E-GEOD-32578 | biostudies-arrayexpress
UnknownThe BRCA1 c.4096+3A>G Variant Displays Classical Characteristics of Pathogenic BRCA1 Mutations in Hereditary Breast and Ovarian Cancers, But Still Allows Homozygous Viability.
Not available
S-EPMC6896150 | biostudies-literature
TranscriptomicsHigh-resolution aCGH analyses of copy number alterations in HER2-amplified breast cancer
HER2 gene amplification and protein overexpression (HER2+) define a clinically challenging subgroup of breast cancer with variable prognosis and response to therapy. Although gene expression profiling has identified an ERBB2 molecular subtype of breast cancer, it is clear that HER2+ tumors reside in...
ORGANISM(S): Homo sapiens 
2010-04-14 | E-GEOD-21259 | biostudies-arrayexpress
TranscriptomicsIdentification of subtypes in HER2-positive breast cancer reveals a gene signature prognostic of outcome
Purpose HER2 gene amplification or protein overexpression (HER2+) defines a clinically challenging subgroup of breast cancer with variable prognosis and response to therapy. We aimed to investigate the heterogeneous biological appearance and clinical behavior of HER2+ tumors using molecular profilin...
ORGANISM(S): Homo sapiens 
2010-03-16 | E-GEOD-18328 | biostudies-arrayexpress
Sort   by:  
 Page size